The agreement, which is subject to the relevant employee consultation processes, is a continuation of Lilly's ongoing transformation of its R&D organization and follows Lilly's selection of Icon to manage its clinical data management business outside of the US, which was announced in November 2008.
Peter Gray, CEO of Icon, said: "The latest announcement marks another milestone in the successful partnership between Icon and Lilly. We have worked together to create a truly flexible model that better meets Lilly's patient and portfolio needs and will also drive productivity within Lilly's clinical operations in Europe. We look forward to continuing to assist Lilly with its transformation initiatives and to delivering the quality services that will expedite their drug development pipelines."
http://www.datamonitor.com
Republication or redistribution, including by framing or similar means, is expressly prohibited without prior written consent. Datamonitor shall not be liable for errors or delays in the content, or for any actions taken in reliance thereon

More News:
Market Updates |
Stock Alerts |
All Trading News |
Stock Index